O-RAN-ALLIANCE-E.V.
15.3.2023 23:28:35 CET | Business Wire | Press release
Memorandum of Understanding between O-RAN ALLIANCE and OpenAirInterface Software Alliance (OAI)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005917/en/
In recently signed Memorandum of Understanding, OAI and O-RAN ALLIANCE agreed to co-operate on open Radio Access Network issues, open source software development, and 5G as well as next generation platforms for demonstrating O-RAN technology. Both organizations will encourage sharing of information in areas of mutual interest and may hold joint meetings and workshops.
”I am very pleased to see the excellent cooperation between O-RAN and OAI,” said Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology, Deutsche Telekom. “The MoU will strengthen our cooperation in development of open source software for the RAN. It will allow a more focused cooperation between both organizations and will enhance our software development.”
“We are very excited at the signing of this MoU,” said Raymond Knopp, President of the OpenAirInterface Software Alliance. “This has been a long standing goal for the OpenAirInterface Software Alliance. Firstly, the OAI software follows the O-RAN architecture and paves the way for showcasing the next generation cellular wireless technologies. Secondly, the two organizations are very complementary in their value propositions. We look forward to capitalizing on this collaboration in the future.”
Two New Open Testing and Integration Centres (OTIC) Approved in Asia & Pacific
O-RAN ALLIANCE announces that Asia & Pacific OTIC by ritt7layers and Asia & Pacific OTIC in Singapore have joined the community of Open Testing and Integration Centres. With this addition there are now 11 approved OTICs across Europe, the Americas, and Asia.
OTICs are vendor-independent, open, and qualified labs approved by the O-RAN ALLIANCE that issue awards in the O-RAN Certification and Badging Program.
For more information about OTICs and O-RAN ALLIANCE’s testing and integration work please visit our website.
O-RAN Release 3 Implements Features with 58 New or Updated Technical Documents
O-RAN Release 003 includes enhancements to RAN Slicing and SMO features. It also introduces new features:
- Security requirements and countermeasures for RAN Intelligent Controller (RIC) interfaces and apps, O-Cloud and O2 interface
- Security technical reports with threat and risk analysis outputs for application lifecycle management, log management, service management and orchestration, shared O-RU
- RIC-enabled massive MIMO optimization for non-Grid of Beams (GoB) beamforming method
- RAN Analytics Information Exposure (RAIE) use cases and RIC architecture enhancements for extending RAN-aware optimization capabilities to external services and applications
O-RAN Release 003 also includes 10 new specification titles:
- Network Energy Savings Use Cases Technical Report
- Decoupled SMO Architecture Technical Report
- Application Protocols for R1 Services
- O1 Interface Specification for Near-RT RIC
- Near-RT RIC APIs specification
- Requirements and Reference Design Specification for Enterprise Microcell
- Study on Security for Application Lifecycle Management
- Study on Security Log Management
- Study on Security for Service Management and Orchestration (SMO)
- Study on Security for Shared O-RU
For more details about newly released O-RAN specifications please read our web announcement. All O-RAN specifications are available for download at our website.
O-RAN Global PlugFest Spring 2023 Set to Start at Labs Across Asia, Europe, and North America
The first of the two O-RAN Global PlugFests planned for 2023 will be held in:
- South Korea hosted by KT
- Taiwan hosted by Auray Technology
- Europe hosted by Deutsche Telekom, EANTC, EURECOM, Orange, Telefónica and Vodafone
- USA hosted by University of New Hampshire InterOperability Laboratory
More than 55 companies have indicated their plan to participate.
Planned activities include interoperability and E2E testing, validation and demonstration of Radio Intelligent Controller (RIC) use cases, as well as X-haul transport, O-Cloud, QoS, and security testing.
F2F Meetings Boost Progress of O-RAN Technical Groups
With the easing of pandemic restrictions, O-RAN ALLIANCE resumed face-to-face meetings of its technical groups, greatly accelerating progress in specifications development. Latest F2F meetings took place in February 2023 in Prague with more than 430 delegates from 115 companies and institutions around the world. O-RAN plans to hold two more F2F meetings in 2023, one in June and one in October.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
